Several phosphodiesterase inhibitors (PDEis) improve cognition, suggesting that an increase in brain cAMP and cGMP facilitates learning and memory. Since extinction of drug-seeking behavior requires associative learning, consolidation and formation of new memory, the present study investigated the efficacy of three different PDEis in the extinction of cocaine-induced conditioned place preference (CPP) in B6129S mice. Mice were conditioned by escalating doses of cocaine which was resistant to extinction by free exploration. Immediately following each extinction session mice received (a) saline/vehicle, (b) rolipram (PDE4 inhibitor), (c) BAY-73-6691 (PDE9 inhibitor) or (d) papaverine (PDE10A inhibitor). Mice that received saline/vehicle during extinction training showed no reduction in CPP for >10 days. BAY-73-6691 (a) dose-dependently increased cGMP in hippocampus and amygdala, (b) significantly facilitated extinction and (c) diminished the reinstatement of cocaine CPP. Rolipram, which selectively increased brain cAMP levels, and papaverine which caused increases in both cAMP and cGMP levels, had no significant effect on the extinction of cocaine CPP. The results suggest that increase in hippocampal and amygdalar cGMP levels via blockade of PDE9 has a prominent role in the consolidation of extinction learning.
AguilarMARodriguez-AriasMMinarroJ (2009) Neurobiological mechanisms of the reinstatement of drug-conditioned place preference. J Brain Res Rev2: 253–277.
2.
AndreevaSGDikkesPEpsteinPMRosenbergPA (2001) Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J Neurosci21: 9068–9076.
3.
ArancioOAntonovaIGambaryanS. (2001) Presynaptic role of cGMP-dependent protein kinase during long-lasting potentiation. J Neurosci21: 143–149.
4.
BaldaMAAndersonKLItzhakY (2006) Adolescent and adult responsiveness to the incentive value of cocaine reward in mice: Role of neuronal nitric oxide synthase (nNOS) gene. Neuropharmacology51: 341–349.
5.
BalesKRPlathNSvenstrupNMennitiFS (2010) Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer’s disease. Neurodegen Dis Top Medicinal Chem6: 57–90.
BoutonME (2002) Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry52: 976–986.
10.
BoutonME (2004) Context and behavioral processes in extinction. Learn Mem11: 485–494.
11.
CarterBLTiffanyST (1999) Meta-analysis of cue-reactivity in addiction research. Addiction94: 327–340.
12.
ChengYFWangCLinHB. (2010) Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats. Psychopharmacology212: 181–191.
13.
DevanBDBowkerJLDuffyKB. (2006) Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology183: 439–445.
14.
DlabogaDHajjhusseinHO’DonnellJM (2006) Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: Comparison with rolipram. Brain Res1096: 104–112.
FisherDASmithJFPillarJSSt DenisSHChengJB (1998) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem273: 15559–15564.
17.
FrancisSHBuschJLCorbinJDSibleyD (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev62: 525–563.
18.
HavermansRCJansenAT (2003) Increasing the efficacy of cue exposure treatment in preventing relapse of addictive behavior. Addict Behav28: 989–994.
19.
ItzhakYAndersonKL (2012) Changes in the magnitude of drug-unconditioned stimulus during conditioning modulate cocaine-induced place preference in mice. Addict Biol17: 706–716.
20.
ItzhakYMartinJL (2002) Cocaine-induced conditioned place preference in mice: induction, extinction and reinstatement by related psychostimulants. Neuropsychopharmacology26: 130–134.
21.
JanesACKantakKMCherryJA (2009) The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens. Psychopharmacology2: 177–185.
22.
KellyMPIsiegasCCheungY. (2007) Constitutive activation of Gs within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. Neuropsychopharmacology32: 577–588.
23.
KleppischTFeilR (2009) cGMP signalling in the mammalian brain: Role in synaptic plasticity and behavior. In cGMP: Generators, Effectors and Therapeutic Implications (Handbook of Experimental Pharmacology, Vol. 191). Berlin: Springer, pp. 549–579.
24.
LuYFKandelERHawkinsRD (1999) Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci23:10250–10261.
25.
MennitiFSFaraciWSSchmidtCJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov5: 660–670.
26.
MiladMRQuirkGJ (2002) Neurons in medial prefrontal cortex signal memory for fear extinction. Nature420: 70–74.
27.
MontiBBerteottiCContestabileA (2006) Subchronic rolipram delivery activates hippocampal CREB and arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology31: 278–286.
28.
MuellerDPerdikarisDStewartJ (2002) Persistence and drug-induced reinstatement of a morphine-induced conditioned place preference. Behav Brain Res136: 389–397.
29.
MuellerDStewartJ (2000) Cocaine-induced conditioned place preference: reinstatement by priming injections of cocaine after extinction. Behav Brain Res115: 39–47.
30.
MuellerEMHofmannSGCherryJA (2010) The type IV phosphodiesterase inhibitor rolipram disturbs expression and extinction of conditioned fear in mice. Neuropharmacology59: 1–8.
OtaKTMonseyMSWuMSSchafeGE (2010) Synaptic plasticity and NO-cGMP-PKG signaling regulate pre- and postsynaptic alterations at rat lateral amygdala synapses following fear conditioning. PLoS ONE5: e11236.
33.
ParkerLAMcDonaldRV (2000) Reinstatement of both a conditioned place preference and a conditioned place aversion with drug primes. Pharmacol Biochem Behav66: 559–561.
34.
PaxinosGFranklinKBJ (2001) The Mouse Brain in Stereotaxic Coordinates, 2nd ed.San Diego, CA: Academic Press, 2001.
35.
PowellJGrayJBradleyB (1993) Subjective craving for opiates: evaluation of a cue exposure protocol for use with detoxified opiate addicts. Br J Clin Psychol32: 39–53.
36.
PowerAEBerlauDJMcGaughJLStewardO (2006) Anisomycin infused into the hippocampus fails to block “reconsolidation” but impairs extinction: the role of re-exposure duration. Learn Mem13: 27–34.
37.
Reyes-IrisarriEMarkerink-Van IttersumMMengodGde VenteJ (2007) Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer’s disease human brains. Eur J Neurosci25: 3332–3338.
38.
RobbinsTWErscheKDEverittBJ (2008) Drug addiction and the memory systems of the brain. Ann NY Acad Sci1141: 1–21.
39.
RodeferJSMurphyERBaxterMG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci21: 1070–1076.
RuttenKDe VenteJSikA. (2005) The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav Brain Res164: 11–16.
42.
SantiniEMullerRUQuirkGJ (2001) Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci21: 9009–9017.
43.
SeegerTFBartlettBCoskranTM. (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res985:113–126.
44.
ShahamYShalevULuLDe WitHStewartJ (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology168: 3–20.
45.
SiegelSRamosBM (2002) Applying laboratory research: drug anticipation and the treatment of drug addiction. Exper Clin Psychopharmacol10: 162–183.
46.
SiuciakJAMcCarthySAChapinDS. (2006) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology51: 374–385.
47.
SonHLuYFZhuoMArancioOKandelERHawkinsRD (1998) The specific role of cGMP in hippocampal LTP. Learn Mem5: 231–245.
48.
ThompsonBESachsBDKantakKMCherryJA (2004) The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice. Eur J Neurosci9: 2561–2568.
49.
TullyTBourtchouladzeRScottRTallmanJ (2003) Targeting the CREB pathway for memory enhancers. Nat Rev Drug Discov2: 267–277.
50.
van der StaayFJRuttenKBärfackerL. (2008) The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology55: 908–918.
51.
van StaverenWCGlickJMarkerink-van IttersumM. (2002) Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J Neurocytol31: 729–741.
52.
van StaverenWCSteinbuschHWMarkerink-van IttersumMBehrendsSde VenteJ (2004) Species differences in the localization of cGMP-producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry. Eur J Neurosci19: 2155–2268.
53.
ZhangHTO’DonnellJM (2000) Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology150: 311–316.
